News

Gestational Diabetes Raises CVD Risk in Overweight Women


 

FROM THE ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES

LISBON – Women with a history of gestational diabetes had an overall 50% elevated risk for cardiovascular events later in life, with a doubled risk among those who were overweight, in a large, case-control, population-based Swedish study.

It is well known that women who have gestational diabetes during pregnancy are at increased risk for type 2 diabetes later in life, but the relationship between gestational diabetes mellitus (GDM) and later cardiovascular disease (CVD) has been less well studied. In this analysis, the first such one to adjust for possible confounders, the increased risk for CVD among women with previous GDM was significant among women with body mass indexes (BMIs) of at least 25 kg/m2, but not below.

Moreover, hypertension and smoking during pregnancy were stronger risk factors than GDM for later CVD. "Preventive strategies after pregnancy might need to be individualized depending on each woman’s characteristics and risk profile," said Dr. Erik Schwarcz, an endocrinologist and senior physician at University Hospital Orebro, Sweden.

Cases in the study, which used data from Swedish National Healthcare Quality registers from 1991 through 2008, were 4,590 women diagnoses with cardiovascular death or a first cardiovascular event – ischemic heart disease, ischemic stroke, peripheral arterial disease, or atherosclerosis – and who gave birth to at least one child during the study period. Those women were each matched with about five age-matched controls – total 22,398 – who did not have cardiovascular disease who gave birth to a child during the same year. Complete data on BMI and smoking were available for 2,660 cases and 13,357 controls.

At the time of the CVD event, the cases had a mean age of 41 years (range 19-61), with a mean of 9 years between the pregnancy and the event. There were 130 deaths among the 2,660 cases, compared with just 2 in the 13,357 controls. Ischemic heart disease and stroke were the most common diagnoses, affecting 56% and 35%, respectively.

A history of GDM was present for 2.4% of the cases, compared with 1.2% of the controls, a significant difference. Also significantly increased among the cases were chronic hypertension (2.1% vs. 0.3%), smoking (35.3% vs. 18.1%), non-Nordic ethnicity (14.1% vs. 11.5%), mean BMI (25.4 vs. 23.9), and low education (23.4% vs. 15.1%).

After adjustment for hypertension, smoking, BMI, parity, education level, and ethnicity, all of the risk factors remained significant except for non-Nordic ethnicity, with odds ratios of 1.50 for GDM, 5.15 for chronic hypertension, and 2.24 for smoking. Using BMI of 20-25 as the referent, a BMI of 25-29 gave an odds ratio of 1.32, while a BMI of 30 or greater doubled the risk (OR, 2.00).

When divided into normal weight (BMI 20-24) versus overweight (BMI 25 or greater), only the overweight women had an increased risk for CVD events (OR, 2.35), while there was no excess CVD risk among those with normal BMI (0.48). When stratified for smoking, GDM was not a risk factor for CVD. In other words, GDM didn’t add any risk above and beyond that of smoking, Dr. Schwarcz explained, adding that the numbers for hypertension were too small to stratify.

In response to an audience member’s question about how many women developed diabetes after pregnancy, Dr. Schwarcz replied that the only available information on that is for prescribed medications and that he is currently analyzing those data.

Dr. Schwarcz disclosed that he has received lecture fees and has conducted clinical trials for Sanofi-Aventis, Novo-Nordisk, and AstraZeneca.

Recommended Reading

Weight Loss Programs Could Save Medicare Up to $15 Billion
MDedge Internal Medicine
Shared Medical Appointments Deliver Effective Diabetes Education
MDedge Internal Medicine
Managing Hypertension Tricky in Certain Diabetes Cases
MDedge Internal Medicine
Bisphosphonate Cancer Risk Divides FDA Officials
MDedge Internal Medicine
Peering Into Pipeline for Weight-Loss Drugs
MDedge Internal Medicine
Antipsychotics Linked to Metabolic Syndrome Spike in Children
MDedge Internal Medicine
FDA Panel: Update Bisphosphonate Labeling
MDedge Internal Medicine
Diabetes Drugs: Type 2 Agents May Have Benefit for Type 1 Disease
MDedge Internal Medicine
In Diabetes, Fatty Food Leads to "Leaky Gut"
MDedge Internal Medicine
Intensive CV Risk Management Failed to Curb Subsequent Events
MDedge Internal Medicine